Abeona Therapeutics Inc
Suletud
5.62 -1.92
Ülevaade
Aktsiahinna muutus
24h
Min
5.61
Max
5.83
Sissetulek | 3.4M -17M |
|---|---|
Müük | 3.3M 8.7M |
P/E Sektori keskmine | 5.894 50.958 |
Kasumimarginaal | -195.814 |
Töötajad | 226 |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | +245.28% upside |
Järgmine tulemuste avaldamine | 13. aug 2026 |
|---|
Turukapital | -4.4M 279M |
|---|---|
Eelmine avamishind | 7.54 |
Eelmine sulgemishind | 5.62 |
Abeona Therapeutics Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Ettevõttest Abeona Therapeutics Inc
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.
